Chemoprevention of Gastric Cancer: Non-steroidal Anti-inflammatory Drugs Including Aspirin.
10.7704/kjhugr.2017.17.4.169
- Author:
Kee Don CHOI
1
Author Information
1. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Keedon@amc.seoul.kr
- Publication Type:Review
- Keywords:
Anti-inflammatory agents, non-steroidal;
Aspirin;
Chemoprevention;
Stomach neoplasms
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
Aspirin*;
Chemoprevention*;
Epithelial Cells;
Helicobacter pylori;
Metabolism;
Prostaglandin-Endoperoxide Synthases;
Stomach Neoplasms*
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2017;17(4):169-174
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Many reports have been published that provide epidemiological evidence supporting the efficacy of aspirin and non-steroidal anti- inflammatory drugs (NSAIDs) in cancer prevention. The presumed mechanism of chemoprevention is inhibition of cyclooxygenase (COX)-2. Aspirin exhibits an anticancerous effect through several inter-related mechanisms: prostaglandin synthesis and catabolism in epithelial cells, inhibition of Wnt-β-catenin signaling, inactivation of platelets, and the host immune response. Several clinical studies have demonstrated that aspirin and NSAIDs exhibit chemopreventive effects in stomach cancer. However, well-designed clinical studies to answer critical clinical questions such as additional benefits of aspirin or NSAIDs after eradication of Helicobacter pylori, and the net benefit despite the adverse effects of long-term intake of aspirin or NSAIDs, are needed.
